We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Poly(ADP-Ribose)Polymerase-1 in Lung inflammatory Disorders: A Review.
- Authors
Sethi, Gurupreet S.; Dharwal, Vivek; Naura, Amarjit S.
- Abstract
Asthma, acute lung injury (ALI), and chronic obstructive pulmonary disease (COPD) are lung inflammatory disorders with a common outcome, that is, difficulty in breathing. Corticosteroids, a class of potent anti-inflammatory drugs, have shown less success in the treatment/management of these disorders, particularly ALI and COPD; thus, alternative therapies are needed. Poly(ADP-ribose)polymerases (PARPs) are the post-translational modifying enzymes with a primary role in DNA repair. During the last two decades, several studies have reported the critical role played by PARPs in a good of inflammatory disorders. In the current review, the studies that address the role of PARPs in asthma, ALI, and COPD have been discussed. Among the different members of the family, PARP-1 emerges as a key player in the orchestration of lung inflammation in asthma and ALI. In addition, PARP activation seems to be associated with the progression of COPD. Furthermore, PARP-14 seems to play a crucial role in asthma. STAT-6 and GATA-3 are reported to be central players in PARP-1-mediated eosinophilic inflammation in asthma. Interestingly, oxidative stress-PARP-1-NF-κB axis appears to be tightly linked with inflammatory response in all three-lung diseases despite their distinct pathophysiologies. The present review sheds light on PARP-1-regulated factors, which may be common or differential players in asthma/ALI/COPD and put forward our prospective for future studies.
- Subjects
OBSTRUCTIVE lung disease treatment; ASTHMA treatment; HORMONE therapy; ADRENOCORTICAL hormones
- Publication
Frontiers in Immunology, 2017, p1
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2017.01172